Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maolactin FMR Supplementation for Exercise Recovery
NCT06436781Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Sep 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by RDC Clinical. Primary endpoint: Change in post exercise muscle breakdown at Week 8. Started Sep 2024; status: completed.
Beyond the preview
Go deeper on NCT06436781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436781.